Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Hepatitis B | Research

The association of HBV infection and head and neck cancer: a systematic review and meta-analysis

Authors: Rukeng Tan, Xinyu Zhu, Yutong Sun, Shihao Yang, Chao Peng, Xinkai Feng, Zengyu Chen, Yiliyaer Yimamu, Guiqing Liao, Le Yang

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Hepatitis B virus (HBV) infections is an important public health problem worldwide and closely affect extrahepatic cancer. Several recent studies have investigated the relationship between HBV infection and head and neck cancer (HNC), but their findings were inconsistent.In order to address the limitations of small sample sizes, we conducted a meta-analysis to assess the association between HBV and HNC.

Methods

We systematically searched PubMed, Web of Science, Embase, Scopus, Cochrane Library, and China National Knowledge Infrastructure from inception to August 2023. Original articles published as a case-control or cohort study were included. HBV infection was identified by HBsAg, HBV DNA or ICD codes. Review articles, meeting abstracts, case reports, communications, editorials and letters were excluded, as were studies in a language other than English or Chinese. According to the MOOSE guidelines, frequencies reported for all dichotomous variables were extracted by two reviewers independently. Similarly, the outcomes of OR, RR or HR, and 95% CIs after adjusting for age and gender were collected.

Results

Thirteen relevant studies and 58,006 patients with HNC were included. Our analysis revealed a positive correlation between HBV and HNC (OR = 1.50; 95% CI: 1.28–1.77). After adjusting for age and gender, the similar result (OR = 1.30; 95% CI: 1.10–1.54) was obtained. Subgroup analysis further demonstrated a significant association between HBV infection and oral cancer (OR = 1.24; 95% CI: 1.05–1.47), as well as nasopharyngeal carcinoma (OR = 1.41; 95% CI: 1.26–1.58). However, due to the limited number of studies included, the statistical significance was not reached for cancer of the oropharynx (OR = 1.82; 95% CI: 0.66–5.05), hypopharynx (OR = 1.33; 95% CI: 0.88-2.00), and larynx (OR = 1.25; 95% CI: 0.69–2.24) after adjusting for age and gender. When excluding the interference of HIV/HCV, smoking and alcohol use, the final outcome (OR = 1.17; 95% CI: 1.01–1.35) got the same conclusion.

Conclusions

Our study confirmed a positive relationship between HNC, specifically oral cancer and nasopharyngeal carcinoma, and HBV infection. However, further investigation is required at the molecular level to gather additional evidence in HNC.
Appendix
Available only for authorised users
Literature
1.
Global regional, national burden of hepatitis B. 1990–2019: a systematic analysis for the global burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022;7(9):796–829.CrossRef
2.
de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Global Health. 2020;8(2):e180–90.CrossRefPubMed
3.
Cui H, Jin Y, Chen F, Ni H, Hu C, Xu Y, Xuan H, Hu D, Deng W, Zhang Y, et al. Clinicopathological evidence of hepatitis B virus infection in the development of gastric adenocarcinoma. J Med Virol. 2020;92(1):71–7.CrossRefPubMed
4.
Liu X, Zhang Z-H, Jiang F. Hepatitis B virus infection increases the risk of pancreatic cancer: a meta-analysis. Scand J Gastroenterol. 2021;56(3):252–8.CrossRefPubMed
5.
Hong SW, Choi W-M, Hwang HW, Kim DS, Yoon J, Lee JW, Shim JH, Yang D-H, Myung S-J, Yang S-K, et al. Chronic viral Hepatitis is Associated with colorectal neoplasia: a systematic review and Meta-analysis. Dig Dis Sci. 2021;66(11):3715–24.CrossRefPubMed
6.
Zhou X, Pan H, Yang P, Ye P, Cao H, Zhou H. Both chronic HBV infection and naturally acquired HBV immunity confer increased risks of B-cell non-hodgkin lymphoma. BMC Cancer. 2019;19(1):477.CrossRefPubMedPubMedCentral
7.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
8.
9.
Ye YF, Xiang YQ, Fang F, Gao R, Zhang LF, Xie SH, Liu ZW, Du JL, Chen SH, Hong MH, et al. Hepatitis B Virus infection and risk of Nasopharyngeal Carcinoma in Southern China. Cancer Epidemiol Biomarkers Prev. 2015;24(11):1766–73.CrossRefPubMed
10.
Wei X-L, Luo H-Y, Li C-F, Jin Y, Zeng Z-L, Ju H-Q, Wu Q-N, Wang Y, Mao M-J, Liu W-L, et al. Hepatitis B virus infection is associated with younger median age at diagnosis and death in cancers. Int J Cancer. 2017;141(1):152–9.CrossRefPubMed
11.
Lu TN, Yang Q, Li M, Zhang JQ, Zou J, Huang L, Lin JH, Jin HS, He JM. HBV infection and extra-hepatic cancers in adolescents and 20s: a retrospective study in China. Cancer Epidemiol. 2018;55:149–55.CrossRefPubMed
12.
Takata Y, Takahashi T, Fukuda J. Prevalence of Hepatitis virus infection in association with oral diseases requiring surgery. Oral Dis. 2002;8(2):95–9.CrossRefPubMed
13.
Kocoglu H, Karaca M, Tural D, Hocaoglu E, Okuturlar Y, Fetullahoglu Z, Gunaldi M, Ciftci R, Tuna S, Yuce OK, et al. Hepatitis B and C rates are significantly increased in certain solid tumors: a large retrospective study. J Cancer Res Ther. 2018;14:774–S778.CrossRef
14.
Dona S, Borsetto D, Fussey J, Biscaro V, Vian E, Spinato G, Menegaldo A, Da Mosto MC, Rigoli R, Polesel J et al. Association between Hepatitis C and B viruses and head and neck squamous cell carcinoma. J Clin Virol 2019, 121.
15.
Komori MF, Kimura T, Kariya S, Onoda T, Takeda S, Mizukawa N, Iida S, Kimata Y, Nishizaki K. Epidemiological correlations between Head and Neck Cancer and Hepatitis B core antibody positivity. Anticancer Res. 2020;40(4):2393–403.CrossRefPubMed
16.
Tian T, Song C, Jiang L, Dai J, Lin Y, Xu X, Yu C, Ge Z, Ding Y, Wen Y, et al. Hepatitis B virus infection and the risk of cancer among the Chinese population. Int J Cancer. 2020;147(11):3075–84.CrossRefPubMed
17.
Mahale P, Engels EA, Koshiol J. Hepatitis B virus infection and the risk of cancer in the elderly US population. Int J Cancer. 2019;144(3):431–9.CrossRefPubMed
18.
Su FH, Chang SN, Chen PC, Sung FC, Huang SF, Chiou HY, Su CT, Lin CC, Yeh CC. Positive Association between Hepatitis C Infection and oral Cavity Cancer: a Nationwide Population-based Cohort Study in Taiwan. PLoS ONE 2012, 7(10).
19.
Kamiza AB, Su F-H, Wang W-C, Sung F-C, Chang S-N, Yeh C-C. Chronic hepatitis infection is associated with extrahepatic cancer development: a nationwide population-based study in Taiwan. BMC Cancer. 2016;16(1):861.CrossRefPubMedPubMedCentral
20.
Song C, Lv J, Liu Y, Chen JG, Ge Z, Zhu J, Dai J, Du LB, Yu C, Guo Y, et al. Associations between Hepatitis B Virus infection and risk of all Cancer types. JAMA Netw Open. 2019;2(6):e195718.CrossRefPubMedPubMedCentral
21.
An J, Kim JW, Shim JH, Han S, Yu CS, Choe J, Lee D, Kim KM, Lim Y-S, Chung Y-H, et al. Chronic hepatitis B infection and non-hepatocellular cancers: a hospital registry-based, case-control study. PLoS ONE. 2018;13(3):e0193232.CrossRefPubMedPubMedCentral
22.
Hong CY, Sinn DH, Kang D, Paik SW, Guallar E, Cho J, Gwak G-Y. Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: a nationwide cohort study. J Viral Hepatitis. 2020;27(9):896–903.CrossRef
23.
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–12.CrossRefPubMed
24.
25.
Yuen M-F, Chen D-S, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, Peters MG, Lai C-L. Hepatitis B virus infection. Nat Reviews Disease Primers. 2018;4:18035.CrossRefPubMed
26.
Min Y, Wei X, Xia X, Wei Z, Li R, Jin J, Liu Z, Hu X, Peng X. Hepatitis B virus infection: an insight into the clinical connection and molecular interaction between hepatitis B virus and host extrahepatic cancer risk. Front Immunol. 2023;14:1141956.CrossRefPubMedPubMedCentral
27.
Jin Y, Gao H, Chen H, Wang J, Chen M, Li G, Wang L, Gu J, Tu H. Identification and impact of hepatitis B virus DNA and antigens in pancreatic cancer tissues and adjacent non-cancerous tissues. Cancer Lett. 2013;335(2):447–54.CrossRefPubMed
28.
Kamiza AB, Fatumo S, Singini MG, Yeh C-C, Chikowore T. Hepatitis B infection is causally associated with extrahepatic cancers: a mendelian randomization study. EBioMedicine. 2022;79:104003.CrossRefPubMedPubMedCentral
29.
Chen Y, Bai X, Zhang Q, Wen L, Su W, Fu Q, Sun X, Lou Y, Yang J, Zhang J et al. The hepatitis B virus X protein promotes pancreatic cancer through modulation of the PI3K/AKT signaling pathway. Cancer Lett 2016, 380(1).
30.
Ho DW-H, Tsui Y-M, Chan L-K, Sze KM-F, Zhang X, Cheu JW-S, Chiu Y-T, Lee JM-F, Chan AC-Y, Cheung ET-Y, et al. Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma. Nat Commun. 2021;12(1):3684.CrossRefPubMedPubMedCentralADS
31.
Khanam A, Chua JV, Kottilil S. Immunopathology of Chronic Hepatitis B infection: role of Innate and Adaptive Immune response in Disease Progression. Int J Mol Sci 2021, 22(11).
32.
Lin G, Zhuang W, Chen XH, Huang C, Lin XD, Huang YJ, Li C. Increase of programmed death ligand 1 in non-small-cell lung cancers with chronic hepatitis B. Annals Oncology: Official J Eur Soc Med Oncol. 2018;29(2):516–7.CrossRef
33.
Zhang X, Tian D, Chen Y, Chen C, He L-N, Zhou Y, Li H, Lin Z, Chen T, Wang Y, et al. Association of Hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy. Transl Lung Cancer Res. 2021;10(7):3191–202.CrossRefPubMedPubMedCentral
34.
Tran BM, Flanagan DJ, Ebert G, Warner N, Tran H, Fifis T, Kastrappis G, Christophi C, Pellegrini M, Torresi J et al. The Hepatitis B Virus Pre-core protein p22 activates wnt signaling. Cancers 2020, 12(6).
35.
Qiu L, Lu F, Zhang L, Wang G, Geng R, Miao Y. HBXIP regulates gastric Cancer glucose metabolism and malignancy through PI3K/AKT and p53 signaling. OncoTargets Therapy. 2020;13:3359–74.CrossRefPubMedPubMedCentral
36.
37.
Xie L, Wang W, Xu B, Liu Y. [Experimental study on hepatitis B-virus X gene expression in adenoid cystic carcinoma]. Hua Xi Kou Qiang Yi Xue Za Zhi = Huaxi Kouqiang Yixue Zazhi = West. China J Stomatology. 2014;32(4):328–30.
38.
Liu X, Li X, Jiang N, Lei Y, Tang LL, Chen L, Zhou GQ, Sun Y, Yue D, Guo R, et al. Prognostic Value of Chronic Hepatitis B Virus infection in patients with nasopharyngeal carcinoma. Cancer. 2014;120(1):68–76.CrossRefPubMed
39.
Weng JJ, Wei JZ, Li M, Lu JL, Qin YD, Jiang H, Qu SH. Effects of Hepatitis B virus infection and antiviral therapy on the clinical prognosis of nasopharyngeal carcinoma. Cancer Med. 2020;9(2):541–51.CrossRefPubMed
40.
Lv JW, Chen YP, Huang XD, Zhou GQ, Chen L, Li WF, Tang LL, Mao YP, Guo Y, Xu RH, et al. Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: a large-scale, big-data intelligence platform-based analysis from an endemic area. Cancer. 2017;123(18):3540–9.CrossRefPubMed
41.
Huang Z, Su B, Liu F, Zhang N, Ye Y, Zhang Y, Zhen Z, Liang S, Liang S, Chen L, et al. YAP1 promotes Tumor Invasion and Metastasis in Nasopharyngeal Carcinoma with Hepatitis B Virus infection. OncoTargets Therapy. 2020;13:5629–42.CrossRefPubMedPubMedCentral
42.
Paul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Hepatitis B Virus Reactivation and Prophylaxis during Solid Tumor Chemotherapy: a systematic review and Meta-analysis. Ann Intern Med. 2016;164(1):30–40.CrossRefPubMed
43.
Lai C-L, Lin C-H, Su Y-C, Shih Y-H, Wang C-C, Teng C-LJ, Chou C-W. Survival outcomes of patients with head and neck squamous cell cancer with hepatitis B virus infection: an analysis from an endemic tertiary center. Cancer Med. 2023;12(6):6802–10.CrossRefPubMed
44.
Global prevalence. Treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403.CrossRef
45.
Yu MC, Yuan J-M. Epidemiology of nasopharyngeal carcinoma. Sem Cancer Biol. 2002;12(6):421–9.CrossRef
Metadata
Title
The association of HBV infection and head and neck cancer: a systematic review and meta-analysis
Authors
Rukeng Tan
Xinyu Zhu
Yutong Sun
Shihao Yang
Chao Peng
Xinkai Feng
Zengyu Chen
Yiliyaer Yimamu
Guiqing Liao
Le Yang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-11967-7

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Systematic Review

The role of piRNAs in predicting and prognosing in cancer: a focus on piRNA-823 (a systematic review and meta-analysis)

Research

The Effect of chemo- and radiotherapy on tumor necrosis in soft tissue sarcoma– does it influence prognosis?

Research

Developing a risk assessment tool for cancer-related venous thrombosis in China: a modified Delphi-analytic hierarchy process study

Research

Gut microbiota composition and metabolic characteristics in patients with Craniopharyngioma

Research

Glycosylation-related genes mediated prognostic signature contribute to prognostic prediction and treatment options in ovarian cancer: based on bulk and single‑cell RNA sequencing data

Research

Stereotactic ablative brachytherapy versus percutaneous microwave ablation for early-stage non-small cell lung cancer: a multicenter retrospective study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits